Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication

PLoS ONE

Volumn 2, Issue 10, 2007, Pages

  Yoo, Min Hyuk ^a   Xu, Xue Ming ^a   Carlson, Bradley A ^a   Patterson, Andrew D ^a   Gladyshev, Vadim N ^b   Hatfield, Dolph L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA DIRECTED DNA POLYMERASE ALPHA; DNA POLYMERASE; K RAS PROTEIN; SELENOPROTEIN; THIOREDOXIN REDUCTASE; THIOREDOXIN REDUCTASE 1; AGAR; ANTIOXIDANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL GROWTH; CELL STRUCTURE; CONTROLLED STUDY; CULTURE MEDIUM; DNA REPLICATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; WESTERN BLOTTING; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; CELL CYCLE; CELL STRAIN 3T3; CHEMISTRY; GENE EXPRESSION REGULATION; METABOLISM; NEOPLASM; PHENOTYPE; TUMOR CELL LINE;

MAMMALIA;

AGAR; ANIMALS; ANTIOXIDANTS; CELL CYCLE; CELL LINE, TUMOR; DNA REPLICATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MODELS, BIOLOGICAL; NEOPLASMS; NIH 3T3 CELLS; PHENOTYPE; SELENOPROTEINS; THIOREDOXIN REDUCTASE 1;

EID: 39749177838     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001112     Document Type: Article

References (26)

1. Hatfield DL, Berry MJ, Gladyshev VN, eds (2006) Selenium: Its molecular biology and role in human health, 2nd ed. New York: Springer Science+Business Media.
2. Irons R, Carlson BA, Hatfield DL, Davis CD (2006) Both selenoproteins and low molecular weight selenocompounds reduce colon cancer risk in mice with genetically impaired selenoprotein expression. J Nutr 136: 1311-1317.
3. Diwadkar-Navsariwala V, Prins. CS, Swanson SM, Birch LA, Ray VH, et al. (2006) Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model. Proc Natl Acad Sci U S A 103: 8179-8184.
4. Kryukov GV, Castellanol S, Novaselov SV, Lobanov AV, Zehtab'O, et al. (2003) Characterization of mammalian selenoproteomes. Science 300: 1439-1443.
5. Gromer S, Eubel JK, Lee BL, Jacob J (2005) Human selenoproteins at a glance. Cell Mol Life Sci 62: 2414-2437.
6. Holmgren A (2006) Selenoproteins of the thioredoxin system. In: Hatfield DL, Berry MJ, Gladyshev VN, eds. Selenium: Its molecular biology and role in human health. 2nd ed. New York: Springer Science+Business Media. pp 183-194.
7. Conrad M, Jakupoglu C, Moreno SG, Lippl S, Banjac A, et al. (2004) Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell Biol 24: 9414-9423.
8. Urig S, Becker K (2006) On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol 16: 452-465.
9. Rundlöf AK, Arnér ES (2004) Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid Redox Signal 6: 41-52.
10. Biaglow JE, Miller RA (2005) The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther 4: 6-13.
11. Arnér ES, Holmgren A (2006) The thioredoxin system in cancer. Semin Cancer Biol 16: 120-426.
12. Fujino G, Noguchi T, Takeda K, Ichijo H (2006) Thioredoxin and protein kinases in redox signaling. Semin Cancer Biol 16: 427-435.
13. Moos PJ, Edes K, Cassidy P, Massuda E, Fitzpatrick FA (2003) Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J Biol Chem 278: 745-750.
14. Nguyen P, Awwad RT, Smart DD, Spitz DR, Gins D (2006) Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett 236: 164-174.
15. Lu J, Chew EH, Holmgren A (2007) Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci. U S A 104: 12288-12293.
16. Yoo MH, Xu. XM, Carlson BA, Gladyshev VN, Hatfield DL (2006) Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 281: 13005-13008.
17. Noda M, Selinger Z, Scolnick EM, Bassin RH (1983) Flat revertants isolated from Kirsten sarcoma virus-transformed cells are resistant to the action of specific oncogenes. Proc Natl Acad Sci U S A 80: 5602-5606.
18. 2+ oscillations in phosphatidylcholine breakdown. Biochem J 283: 347-354.
19. Hanaban D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
20. Pavlov YI, Shcherbakova PV, Rogozin IB (2006) Roles of DNA polymerases in replication, repair, and recombination in eukaryotes. Int Rev Cytol 255: 41-132.
21. Arner ES, Holmgren A (2000) Physiological functions of thioredoxin and thioredoxin reductase, Eur J Biochem 267: 6102-6109.
22. Muller EG (1994) Deoxyribonucleotides are maintained at normal levels in a yeast thioredoxin mutant defective in DNA synthesis. J Biol Chem 269: 24466-24471.
23. Koc A, Mathews CK, Wheeler LJ, Gross MK, Merrill GF (2006) Thioredoxin is required for deoxyribonucleotide pool maintenance during S phase. J Biol Chem 281: 15058-15063.
24. Novoselov SV, Calvisi DF, Labunskyy VM, Factor VM,,Carlson BA, et al. (2005) Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice. Oncogene 24: 8003-8011.
25. Gladyshev VN, Jeang K-T, Wootton JC, Hatfield DA (1998) New human selenium-containing protein: purification, characterization and cDNA sequence. J Biol Chem 273: 8910-8915.
26. Gladyshev VN, Stadtman T, Hatfield DL, Jeang K-T (1999) Levels of major selenoproteins in T cells decrease during HIV infection and low molecular mass selenium compounds increase. Proc Natl Acad Sci U S A 96: 835-839.